What is the best way to treat lung cancer? What is the specific chemotherapy regimen for lung cancer treated by PDD?

The cycle of chemotherapy for lung cancer depends on the patient's condition. Different conditions and different constitutions will result in different chemotherapy times. The chemotherapy cycle is generally three to four weeks, during which transaminases and white blood cells should be checked regularly. The next chemotherapy can only be carried out if the indicators are qualified. As a common chemotherapy drug for lung cancer, is there any specific chemotherapy regimen? 1. Vinorelbine + cisplatin (NC) regimen is an early third-generation regimen. In a phase III clinical study by the Southwest Oncology Group (SEOG) in the United States, 206 patients with advanced non-small cell lung cancer were randomly divided into the vinorelbine + cisplatin group and the cisplatin monotherapy group. Research results: The total effective rate was 26%, the median survival time was 8 months, and the 1-year survival rate was 36%, which was significantly better than cisplatin monotherapy. 2. The gemcitabine + cisplatin (GC) regimen is one of the commonly used treatment regimens for NSLSC recently. In a phase III clinical study published in 1999, the GC regimen was compared with the first-generation standard regimen Ep (cisplatin + etoposide), with an effective rate of 40.6% vs. 21.9% (p = 0.02), a median disease progression time of 6.9 months vs. 4.3 months (p = 0.01), and a median survival time of 8.7 months vs. 7.2 months (p = 0.40). 3. Paclitaxel + cisplatin (pC) regimen. This pC regimen replaced the Ep regimen as the standard first-line treatment for advanced NSCLC. In many subsequent years, the pC regimen was used as the control group in clinical studies of chemotherapy regimens. However, in 2007, a retrospective analysis of chemotherapy regimens for advanced NSCLC showed that the pC regimen had comparable short-term effective rates to other third-generation platinum-containing regimens, but had a shorter disease-free progression time (pFS), and was not an advantageous regimen for first-line chemotherapy of advanced NSCLC.